)

Immunovant (IMVT) investor relations material
Immunovant Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic focus and product pipeline
Pursuing a broad anti-FcRn strategy with IMVT-1402, targeting autoantibody-driven diseases and aiming for best-in-class efficacy and convenience across multiple indications.
IMVT-1402 is positioned as a potential first- and best-in-class product, with robust IgG lowering, favorable safety, and simple autoinjector delivery.
Ongoing and planned registrational trials span Graves' disease, Sjögren's disease, difficult-to-treat rheumatoid arthritis, CIDP, MG, and CLE, addressing over 600,000 US patients.
Strong patent protection extends to 2043, supporting long-term commercial potential.
Cash balance of ~$600 million as of June 2025 provides runway through key clinical readouts.
Clinical evidence and differentiation
Deeper IgG reduction with anti-FcRn therapy correlates with improved clinical outcomes across multiple autoimmune indications.
IMVT-1402 and batoclimab demonstrate best-in-class IgG reductions (up to ~80%), outperforming competitors in cross-trial comparisons.
Phase 3 batoclimab data in MG showed highest MG-ADL reduction and minimal symptom expression rates among global trials.
Batoclimab CIDP Phase 2b data showed 84% response rate in patients with ≥70% IgG reduction, informing IMVT-1402 trial design.
IMVT-1402 is delivered via a user-friendly, market-proven autoinjector, supporting at-home or HCP administration.
Market opportunity and unmet need
Large total addressable market with 20+ indications in development across the anti-FcRn class, including neurology, endocrinology, rheumatology, dermatology, and renal diseases.
Graves' disease: ~880K US prevalence, with ~330K relapsed, uncontrolled, or intolerant to ATDs, and ~20K annual incident second-line patients.
Myasthenia gravis: 59K–116K US patients, with 35% not well-controlled on standard of care and high rates of residual symptoms on current therapies.
CIDP: 58K US patients, with 30–50% inadequately controlled on existing therapies and high demand for improved response and convenience.
D2T RA: 5–20% of 1.5M US RA patients are difficult-to-treat, representing a 70K addressable population needing new options.
Sjögren's disease: 290K US prevalence, no approved therapies, and 90K addressable patients with moderate-to-severe disease.
CLE: 153K US prevalence for SCLE and CCLE, with up to 50% non-responders to current therapies and no novel treatments in over 50 years.
Next Immunovant earnings date

Next Immunovant earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage